OBJECTIVES:  The recent reforms and policy changes have increased the cost pressures on all healthcare stakeholders, including clinical experts. In the past, clinical guidelines were developed independent of cost or economic considerations. However, increasingly, more clinical guidelines are mentioning cost concerns and referring to economic data in new recommendations. The objective of this study was to analyze trends in the use of health economic information for developing clinical guidelines. METHODS:  A systematic literature search was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines published between 2003-2012 were included. For guidelines which met the search criteria, data was collected for the name of the authors, indication, year of publication, country/region, and context of use of cost/economic evidence. RESULTS: Sixteen clinical guidelines published between 2003-2014 met the inclusion criteria for specific mention of cost/economic evidence. More than 50% of these guidelines were published between 2006-2014.  For indication, 3 out of 16 guidelines were for diabetes, while the rest were for different indications. In these16 guidelines “cost effectiveness” was mentioned 14 times, either referencing cost-effectiveness data or to mention the importance of such data for selecting treatment options. The guidelines commonly cite high cost of disease or high economic burden as one of the considerations for developing new recommendations (11 out of 16). Another term that was commonly used by these guidelines was “cost-benefit,” which was mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 out of 16 times) in these guidelines. CONCLUSIONS: This analysis suggests that some clinical experts groups are increasingly showing willingness to use and incorporate health economic information for developing new recommendations. Findings from this study might aid drug and device manufacturers in understanding the context of use of such information and allow them to tailor their product development plans for generating such evidence.